Aldeyra Therapeutics
the primary of reduction of retinal detachment historical control was achieved | Aldeyra Therapeutics
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
9 of 13
Related slides by other companies
Aeglea BioTherapeutics
Results
December 2021
primary met marked and sustained reduction in plasma arginine | Aeglea BioTherapeutics
NeuroSense Therapeutics
Investor Presentation
December 2023
phase study results achieved primary with a safety and tolerability profile comparable to placebo | NeuroSense Therapeutics
SAB Biotherapeutics
Results
September 2022
sab met the primary of viral load and secondary of symptom reduction i win | SAB Biotherapeutics
Theravance Biopharma
Investor Conference
November 2022
| Theravance Biopharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io